Coronary stent fracture and restenosis in the drug-eluting stent era: do we have clues of management?
Despite the fact that the drug-eluting stents (DES) have markedly reduced neointimal proliferation, restenosis is still an open subject. Although DES fracture is very rare, it has been considered as one of the reasons for DES restenosis, however, the mechanism and proper management are not clearly elucidated yet. We describe two cases of sirolimus-eluting stent fracture combined with significant restenosis and suggest the possible revascularization strategies for successful management.
Kim
Eung Ju
EJ
Rha
Seung-Woon
SW
Wani
Sunil P
SP
Suh
Soon Yong
SY
Choi
Cheol Ung
CU
Kim
Jin Won
JW
Park
Chang Gyu
CG
Seo
Hong Seog
HS
Oh
Dong Joo
DJ
D000368:Aged; D023903:Coronary Restenosis / Q000209:etiology* / Q000628:therapy*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D011475:Prosthesis Failure; D020123:Sirolimus / Q000008:administration & dosage; D015607:Stents / Q000009:adverse effects*
D007166:Immunosuppressive Agents; D017239:Paclitaxel; D020123:Sirolimus